Aspire Biopharma Holdings Inc. Common Stock (ASBP)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, generate cash, and possess some durable advantage. Aspire Biopharma does not currently meet those tests. In fiscal Q2 2026 (the quarter ended 2026-06-30), revenue was $63,104 and net income was -$1.3M. In fiscal Q1 2026 (the quarter ended 2026-03-31), revenue was $28,353 and net income was -$3.2M. For FY2025 (the period ended 2025-12-31), revenue was $6,202 and net income was -$24.5M. FY2023 net income was $4.5M, which is why FairStock labels it TURNAROUND — loss in the latest year after earlier profits. The revenue base is microscopic, and the losses are large. There is no visible moat; the sublingual drug-delivery work and automotive/industrial controls are early-stage or tiny relative to the losses. At the 2026-10-13 close of $8.18, market cap was $1.1M. FairStock's calculations show P/E -1.15, P/B 0.24, EPS -$7.09, ROE -1032.14%, D/E 0.39, trailing free cash flow -$7.2M, and FCF yield -660.6%. FairStock's Piotroski F-Score is 3/9 and Altman Z-Score is -2.46. The low P/B might attract a bargain hunter, but negative earnings and cash burn can consume book value. ROCE of 60.58% is a FairStock figure that is hard to trust alongside such losses. Growth from almost nothing is not yet a business. I would need consistent revenue, narrowing losses, and positive cash flow before calling this a sound value proposition.

In plain English: Aspire Biopharma Holdings works on a medicine-delivery technology and also makes automotive and industrial control systems. The business looks weak today: it brings in very little sales and is losing a lot of money. The shares look cheap compared with the value of its net assets on paper, but the heavy losses and cash burn make it hard to call them a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K/A (period ended 2025-12-31) · FY2024 10-K/A (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer